Colorectal Cancer
Conditions
Brief summary
To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers
Interventions
PROCEDURESampling
After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples. The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern: * Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal * Peritoneal liquid * none tumoral peritoneum * Portal blood * Peripheral blood * Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum. In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Histological Diagnosis of stage IV colorectal cancer * Hepatic metastasis and/or peritoneal potentially resecable * Patient affiliated with a mode of the social security or recipient of such a mode * Information of the patient or his legal representative and collection of his assent
Exclusion criteria
* None metastatic colorectal cancer * Cancer of appendicular origin * Patients deprived of liberty or unable to give his assent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification and characterization of the tumoral intermediaries on the overflowing peritoneal | Up to 24 months | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. |
| Identification and characterization of the tumoral intermediaries on the portal blood | Up to 24 months | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. |
| Identification and characterization of the tumoral intermediaries on the peripheral blood | Up to 24 months | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. |
| Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal) | Up to 24 months | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. |
Countries
France
Contacts
Primary ContactDiane GOERE, MD
Backup ContactFanny JAULIN, MD
Outcome results
None listed